These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30227062)

  • 1. Improving the Quality of Compounded Sterile Drug Products: A Historical Perspective.
    Cantrell SA
    Ther Innov Regul Sci; 2016 May; 50(3):266-269. PubMed ID: 30227062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
    Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
    Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
    Pinkerton JV; Pickar JH
    Menopause; 2016 Feb; 23(2):215-23. PubMed ID: 26418479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sterile compounding: clinical, legal, and regulatory implications for patient safety.
    Qureshi N; Wesolowicz L; Stievater T; Lin AT
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1183-91. PubMed ID: 25443512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How gaps in regulation of compounding pharmacy set the stage for a multistate fungal meningitis outbreak.
    Teshome BF; Reveles KR; Lee GC; Ryan L; Frei CR
    J Am Pharm Assoc (2003); 2014; 54(4):441-5. PubMed ID: 25063265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of sterile product compounding practices in Canadian hospital pharmacies.
    Fitch DP; Hall KW
    Can J Hosp Pharm; 1993 Dec; 46(6):249-60. PubMed ID: 10131343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists.
    Quertermous J; Desai S; Harper J; Lebwohl M; Torres A; Kircik LH
    J Drugs Dermatol; 2018 Jul; 17(7):s17-s22. PubMed ID: 30005109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multistate fungal meningitis outbreak -- interim guidance for treatment.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Oct; 61(41):842. PubMed ID: 23076094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy - United States, 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Oct; 61(41):839-42. PubMed ID: 23076093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extemporaneous Compounding: Selective Pharmacists with Separate Skill.
    Mohiuddin AK
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacy compounding of high-risk level products and patient safety.
    Mullarkey T
    Am J Health Syst Pharm; 2009 Sep; 66(17 Suppl 5):S4-13. PubMed ID: 19710449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National survey of quality assurance activities for pharmacy-prepared sterile products in hospitals and home infusion facilities--1995.
    Santell JP; Kamalich RF
    Am J Health Syst Pharm; 1996 Nov; 53(21):2591-605. PubMed ID: 8913388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy.
    Sunenshine RH; Tan ET; Terashita DM; Jensen BJ; Kacica MA; Sickbert-Bennett EE; Noble-Wang JA; Palmieri MJ; Bopp DJ; Jernigan DB; Kazakova S; Bresnitz EA; Tan CG; McDonald LC
    Clin Infect Dis; 2007 Sep; 45(5):527-33. PubMed ID: 17682984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outbreak of bacteremia due to Burkholderia contaminans linked to intravenous fentanyl from an institutional compounding pharmacy.
    Moehring RW; Lewis SS; Isaacs PJ; Schell WA; Thomann WR; Althaus MM; Hazen KC; Dicks KV; Lipuma JJ; Chen LF; Sexton DJ
    JAMA Intern Med; 2014 Apr; 174(4):606-12. PubMed ID: 24493147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U.S. Compounding Pharmacy-Related Outbreaks, 2001-2013: Public Health and Patient Safety Lessons Learned.
    Shehab N; Brown MN; Kallen AJ; Perz JF
    J Patient Saf; 2018 Sep; 14(3):164-173. PubMed ID: 26001553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compounding for animal patients: contemporary issues.
    Lust E
    J Am Pharm Assoc (2003); 2004; 44(3):375-84; quiz 384-6. PubMed ID: 15191248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sterile Compounding Pharmacies: States That Do and Do Not Require Compliance With USP <797> Versus FDA 483s.
    Wilson M
    Ther Innov Regul Sci; 2016 May; 50(3):279-303. PubMed ID: 30227076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Centralized insourcing of sterile compounding: One multihospital health system's journey.
    Bracero D; Carlos Pagan L; Rowe A; Cassano AT
    Am J Health Syst Pharm; 2022 Jul; 79(15):1281-1289. PubMed ID: 35443036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.